2018 Current Fiscal Year Report: Chronic Fatigue Syndrome Advisory Committee

Report Run Date: 04/25/2024 10:40:09 AM

1. Department or Agency 2. Fiscal Year

Department of Health and Human

Services

3b. GSA

2018

3. Committee or Subcommittee

Committee No.

14c.

Chronic Fatigue Syndrome Advisory

Committee

5136

4. Is this New During 5. Current 6. Expected 7. Expected Fiscal Year? Charter Renewal Date **Term Date**

No 09/05/2016

8b. Specific 8a. Was Terminated During 8c. Actual **Termination** FiscalYear? Term Date Authority

Yes 09/05/2018

9. Agency 10b. 10a. Legislation

Recommendation for Next Legislation Reg to Terminate? Pending? **FiscalYear**

Continue No Not Applicable

11. Establishment Authority Authorized by Law

12. Specific 13. 14.

Effective Establishment Commitee Presidential?

Authority Type Date

42 USC 217a, Section

222

09/05/2002 Continuing No

15. Description of Committee Scientific Technical Program

Advisory Board

16a. Total

Number of

No Reports for

this FiscalYear

Reports

2 17b. Closed 0 17c. Partially Closed 0 Other Activities 0 17d. Total 2

Meetings and Dates

Purpose Start End The first of two required annual meeting to discuss progress on a number of issues and 12/13/2017 - 12/14/2017 work groups updates and recommendations to the entire Committee. The second of two required annual meeting to discuss progress on a number of issues

and work groups updates and recommendations to the entire Committee.

06/20/2018 - 06/21/2018

Number of Committee Meetings Listed: 2

	Current FY FY
18a(1). Personnel Pmts to	\$13,000.00\$0.00
Non-Federal Members	ψ13,000.00 ψ0.00
18a(2). Personnel Pmts to	\$0.00\$0.00
Federal Members	ψο.σο ψο.σο
18a(3). Personnel Pmts to	\$123,272.00\$0.00
Federal Staff	ψ123,212.00ψ0.00
18a(4). Personnel Pmts to	\$0.00\$0.00
Non-Member Consultants	ψ0.00 ψ0.00
18b(1). Travel and Per Diem	\$28,000.00\$0.00
to Non-Federal Members	Ψ20,000.00 Ψ0.00
18b(2). Travel and Per Diem	\$0.00\$0.00
to Federal Members	ψ0.00 ψ0.00
18b(3). Travel and Per Diem	\$0.00\$0.00
to Federal Staff	ψο.σο ψο.σο
18b(4). Travel and Per Diem	\$0.00\$0.00
to Non-member Consultants	ψο.σο ψο.σο
18c. Other(rents,user	
charges, graphics, printing,	\$25,547.00\$0.00
mail, etc.)	
18d. Total	\$189,819.00\$0.00
19. Federal Staff Support	1.50 0.00
Years (FTE)	1.50 0.00

20a. How does the Committee accomplish its purpose?

The Committee advises and makes recommendations to the Secretary, through the Assistant Secretary for Health, on a range of topics including: (1) opportunities to improve knowledge and research about the epidemiology, etiologies, biomarkers and risk factors for ME/CFS; (2) research on the diagnosis, treatment, and management of ME/CFS and potential impact of treatment options; (3) strategies to inform the public, health care professionals, and the biomedical academic and research communities about ME/CFS advances; (4) partnerships to improve the quality of life of ME/CFS patients; and (5) strategies to insure that input from ME/CFS patients and caregivers is incorporated into HHS policy and research.

20b. How does the Committee balance its membership?

The Chronic Fatigue Syndrome Advisory Committee (CFSAC) serves to provide science-based advice and recommendations to the Secretary, through the Assistant Secretary for Health, on a broad range of issues and topics pertaining to myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and other related health conditions. The Committee brings together leading scientists, advocacy groups, patients diagnosed with ME/CFS, caretakers, and representatives from federal agencies to discuss advances in the diagnosis, treatment and prevention of ME/CFS. The Committee is comprised of 13 voting members with expertise in biomedical research in the area of ME/CFS, health care delivery services, insurers, voluntary organizations concerned with the problems of individuals with ME/CFS and patients and care givers. The voting members are appointed to serve overlapping terms of up to four years. The voting members are appointed by the Secretary. The Committee structure also includes eight non-voting, ex-officio members who represent the following five HHS agencies: Agency for Healthcare Research and Quality, Centers for

Disease Control and Prevention, the Food and Drug Administration, the National Institutes of Health and the Health Resources and Services Administration plus three other federal agencies: the Social Security Administration, the Department of Veterans Affairs, and the Department of Defense. The non-voting ex-officio members provide critical information regarding their respective agency's activities related to ME/CFS at each Committee meeting. Composition of the Committee also includes three non-voting liaison representative positions occupied by individuals who are selected by their organizations to serve the interests of their respective organization. These organizations have interest in the work being done to properly address ME/CFS. The representative organizations are selected by the Designated Federal Officer (DFO) or designee and serve a term of two years. The following organizations currently occupy the non-voting representative positions on the Committee: (1) ME Action; (2) Massachusetts CFIDS/ME & FM Association; (3) Simmaron Research Inc.

20c. How frequent and relevant are the Committee Meetings?

The Committee is authorized to meet not less than two times a year. The Committee meets to receive, as well as share information about work that is being done to properly address this important public health concern.

20d. Why can't the advice or information this committee provides be obtained elsewhere?

The establishment of this Committee was in the public interest. Chronic fatigue syndrome is a very debilitating health condition. Utilizing individuals who have knowledge and expertise in biomedical research, health care delivery services, and the

problems of individuals living with ME/CFS will assist in developing departmental efforts to properly address this important public health concern.

20e. Why is it necessary to close and/or partially closed committee meetings?

CFSAC meetings are open to the public.

21. Remarks

At the first CFSAC meeting of FY18 held in December 2017, the Committee made a total of ten recommendations to HHS. 1. CFSAC asked HHS to disseminate the treatment recommendations in the 2014 IACFS/ME Adult Primer and in the 2017 ME/CFS Pediatric Primer; CFSAC asked the CDC to continue to move forward with the June 2017 CFSAC recommendation to create a plan for developing clinical practice guidelines for ME/CFS; 3. CFSAC recommended that all educational materials disseminated by the HHS, VA and DoD for healthcare providers and for the general public be informed by the findings of the IOM, the IACFS/ME 2014 Adult Primer and 2017 ME/CFS Pediatric Primer: 4. CFSAC recommended that all outdated federal websites or outdated material provided by federal agencies be removed or updated as quickly as possible and by no later than the end of 2018; 5. CFSAC recommended that the materials provided by HHS, the VA and the DoD are to be regularly reviewed and updated as warranted by the research and consensus expert opinion; 6. a. CFSAC recommended that the agencies within the HHS provide sufficient funding for ME/CFS Project ECHO (Extension for Community Health Outcomes) programs, b. Provide funding for CME/CE training conferences/programs on ME/CFS led by experts

for MD, DO, NP, PA, Nurses, Social Workers, Psychologists, Psychiatrists, c. Continue school health and pediatric ME/CFS educational initiatives as recommended in January 12-13, 2017 in person CFSAC meeting, d. Continue outreach to professional medical societies, internet medical provider information websites (e.g. UpToDate), and internet "public" medical websites (e.g. Mayo Clinic, Healthwise) to inform them of new information on the CDC and other federal agency websites; 7. Recommended that all materials published or distributed by HHS take special care to address negative provider attitudes and disease stigma; 8. a. Recommends that AHRQ works to get the 2016 Addendum of the 2014 ME/CFS AHRQ Evidence Review published in the Annals of Internal Medicine; 9. Endorsed the IAFCS/ME's proposal for changes to the ICD-10-CM coding for ME/CFS and 10. Recommended that CMS be added as an ex officio when the charter is renewed in 2018. At the second CFSAC meeting of FY18 held in June 2018, the Committee made a total of four recommendations to HHS. 1. CFSAC recommended that the National Center for Health Statistics work with ME/CFS experts and advocates to resolve concerns regarding the IACFS/ME proposal of how to reclassify CFS in the ICD-10-CM and ensure that the IACFS/ME proposal is placed on the agenda for the September 2018 meeting; 2. CFSAC recommended that CDC add a "diagnostic coding" section to its ME/CFS website for medical providers to explain that the code for "chronic fatigue, unspecified" (R53.82) should not be used for ME/CFS, and direct providers to use the existing code for myalgic encephalomyelitis or post viral fatigue (G93.3) when coding the diagnosis of ME/CFS; 3. CFSAC recommended

information and outreach to medical providers should include this diagnostic coding clarification related to a diagnosis of ME/CFS; aand 4. CFSAC endorsed the establishment of an ME/CFS Project ECHO (Extension for Community Healthcare Outcomes) or equivalent tele-mentoring program, to be conducted by ME/CFS disease experts and established through an existing academic center Project ECHO. Thus, CFSAC recommends that the relevant HHS agencies, including but not limited to CDC, HRSA, and AHRQ, plus the VA and DOD, evaluate the feasibility of supporting and promoting an ME/CFS Project ECHO and identifying potential grants, contracts, or other funding mechanisms that could be used to support the development of ME/CFS ECHO from the relevant agencies. Committee members Alisa Koch, Jose Montoya, Donna Pearson and Faith Newton were extended up to 180 days. The members' term ended on 9.5.18 when the charter expired and the Committee was terminated.

that all federal agencies providing ME/CFS

Designated Federal Officer

Gustavo Ceinos Senior Public Health Analyst, Office on Women's Health

Committee	Start	End	Occupation	Member
Members	Otal t		o o o a parion	Designation
Bateman, Lucinda	12/13/2017	09/05/2018	Physician	Special Government Employee (SGE) Member
Belay, Ermias	01/01/2016	09/05/2018	Associate Director for Epidemiologic Science, CDC	Ex Officio Member
Cook, Dane	05/10/2010	11/10/2017	Assistant Professor, Kinesiology	Special Government Employee (SGE) Member
HsuBorger, Ben	06/19/2017	09/05/2018	Community Organizer	Representative Member
Kaplan, Gary	11/01/2013	11/10/2017	Physician	Special Government Employee (SGE) Member

Koch, Alisa Lange,	06/16/2014	09/05/2018	Eli Lilly	Special Government Employee (SGE) Member Special Government
Gudrun	12/13/2017	09/05/2018	Researcher	Employee (SGE) Member Special
Levine, Susan	05/10/2010	11/10/2017	CFS practitioner	Government Employee (SGE) Member
Maynard, Janet	01/01/2016	09/05/2018	Clinical Team Leader, Division of Pulmonary, Allergy, and Rheumatology Products, FDA	Ex Officio Member
Miller, Courtney	06/19/2017	09/05/2018	Simmaron Research Board President	Representative Member
Montoya, Jose	06/16/2014	09/05/2018	University School of Medicine	Special Government Employee (SGE) Member
Newton, Faith	07/01/2014	09/05/2018	Associate Professor Education, Delaware State University	Special Government Employee (SGE) Member
Pearson, Donna	06/16/2014	09/05/2018	Patient Advocate	Special Government Employee (SGE) Member
Sanchez, Carmen	02/08/2018	09/05/2018	Education Program Specialist	Ex Officio Member
Shahzad, Amrit	12/13/2017	09/05/2018	Researcher	Special Government Employee (SGE) Member
Tracy, Christopher	02/01/2018	09/05/2018	Chief, Rheumatology Services (DoD)	Ex Officio Member
Whittemore, Vicky	01/01/2016	09/05/2018	Program Director, National Institute of Neurological Disorders and Stroke, NIH	Ex Officio Member
Williams, Cheryl	01/01/2016	09/05/2018	Director, Office of Medical Policy, SSA	Ex Officio Member
Williams, Leah	06/19/2017	09/05/2018	MassCFIDS Treasurer	Representative Member

Narrative Description

CFSAC supports the Department's efforts to advance the health and well-being of Americans and the Department's strategic goal of enhancing the capacity and productivity of the Nation's health science research enterprise. CFSAC provides expert advice and recommendations to the Secretary and the Assistant Secretary for Health on topics, incuding the epidemiology and risk factors relating to myalgic encephalomyelitis and chronic fatigue syndrome (ME/CFS) and diagnosis and treatment methods for the condition. The Committee also advises on the development and implementation of programs to inform the public, health care professionals, and the biomedical, academic, and research communities about advances related to CFS.

What are the most significant program outcomes associated with this committee?

	Checked if	
	Applies	
Improvements to health or safety		✓
Trust in government		✓
Major policy changes		✓
Advance in scientific research		✓
Effective grant making		
Improved service delivery		✓
Increased customer satisfaction		✓
Implementation of laws or regulatory		
requirements		
Other		

Outcome Comments

Since the inception of the Committee, the CFSAC website has been updated with links to other federal partners regarding ME/CFS and tools for caregivers and patients. Public testimonies have been posted to the website. The public has responded favorably to the CFSAC listserv established in June 2012 to provide additional means of communicating/disseminating information pertaining to CFSAC. A listening only telephone line is provided during all CFSAC meetings so the public could listen to the meetings.

What are the cost savings associated with this committee? **Checked if Applies** None Unable to Determine Under \$100,000 \$100,000 - \$500,000 \$500,001 - \$1,000,000 \$1,000,001 - \$5,000,000 \$5,000,001 - \$10,000,000 Over \$10,000,000 Cost Savings Other **Cost Savings Comments** NA What is the approximate Number of recommendations produced by this committee for the life of the committee? 112 **Number of Recommendations Comments** Some recommendations overlap. What is the approximate Percentage of these recommendations that have been or will be Fully implemented by the agency? 32% % of Recommendations Fully Implemented Comments N/A What is the approximate Percentage of these recommendations that have been or will be Partially implemented by the agency? 6% % of Recommendations Partially Implemented Comments

Does the agency provide the committee with feedback regarding actions taken to implement recommendations or advice offered?

NA

Yes No Not Applicable			
Agency Feedback Comments The DFO communicates with the Committee Chair through regular conference calls and emails. Additional information pertaining to the Committee and other ME/CFS-related matters can be found on the Committee website. The ex-officio members and the DFO report on the status of Departmental efforts at each public meeting. The website is http://www.hhs.gov/advcomcfs/.			
What other actions has the agency to recommendation?	aken as a result of the committee's advice or		
	Checked if Applies		
Reorganized Priorities	✓		
Reallocated resources	v.n.:		
Issued new regulation			
Proposed legislation			
Approved grants or other payments			
Other			
Action Comments During each Committee meeting, the ex-officio members provide updated information regarding efforts and/or actions being undertaken by their respective agency to respond to the Committee's recommendations. Is the Committee engaged in the review of applications for grants?			
No			
Grant Review Comments NA			
How is access provided to the information for the Committee's documentation?			
	Checked if Applies		
Contact DFO	X		
Online Agency Web Site	₩		
Online Committee Web Site	⊻		
Online GSA FACA Web Site	✓		
Publications			
Other			

Access Comments

N/A